Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press32910.17650/1994-4098-2009-0-3-4-125-129GYNECOLOGY. NEW TECHNOLOGIESГИНЕКОЛОГИЯ. НОВЫЕ ТЕХНОЛОГИИTARGET THERAPY FOR DISSEMINATED CANCER OF THE CERVIX UTERIТАРГЕТНАЯ ТЕРАПИЯ ДИССЕМИНИРОВАННОГО РАКА ШЕЙКИ МАТКИGorbunovaV. A.ГорбуноваВ. А.
Russian Federation
OdintsovaA. vОдинцоваА. С.
Russian Federation
KhokhlovaS. V.ХохловаС. В.
Russian Federation
sv.khohlova@mail.ruDepartment of Chemotherapy, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowОтделение химиотерапии ГУ РОНЦ им. Н.Н. Блохина РАМН, Москва101120093-412512915092014150920142009https://ojrs.abvpress.ru/ojrs/article/view/329

The paper gives recent data on the use of target agents, such as erlotinib, gefitinib, cetuximab, bevacizumab, and sorafinib in advanced cancer of the cervix uteri (CCI). Approaches using target drugs in combination with chemotherapy are of the greatest interest. A spec- trum of molecular biomarkers (epidermal and vascular growth factors) in CCI and its correlation with prognosis and treatment response are shown. A number of adverse relations caused by target agents are considered.

Представлены новые данные изучения применения таргетных препаратов, таких как эрлотиниб, гефитиниб, цетуксимаб, бевацизумаб, сорафениб, при распространенном раке шейки матки (РШМ). Наибольший интерес вызывают подходы с использованием таргетных пре- паратов в комбинации с химиотерапией. Показан спектр молекулярно-биологических маркеров при РШМ (эпидермального и сосудистого факторов роста) и корреляция с прогнозом заболевания и ответом на лечение. Рассматривается ряд побочных эффектов, связанных с ис- пользованием таргетных препаратов.

advanced cervical cancermolecular biomarkerstarget therapyраспространенный рак шейки маткимолекулярно-биологические маркерытаргетные препараты1. Давыдов М., Аксель Е. Статистика злокачественных новообразований в России и странах СНГ в 2004 г. М., 2006.Давыдов М., Аксель Е. Статистика злокачественных новообразований в России и странах СНГ в 2004 г. М., 2006.2. Ременник Л.В., Новикова Е.Г., Мокина В.Д. и др. Злокачественные новообразования женских половых органов. Рос онкол журн 1997;(6):4—8.Ременник Л.В., Новикова Е.Г., Мокина В.Д. и др. Злокачественные новообразования женских половых органов. Рос онкол журн 1997;(6):4—8.3. Gaffney D.K., Haslam D., Tsodikov A. et al. Epidermal growth fac- tor receptor (EGFR) and vascular endothelial growth factor (VEGF) nega- tively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003;56(4):922—8.Gaffney D.K., Haslam D., Tsodikov A. et al. Epidermal growth fac- tor receptor (EGFR) and vascular endothelial growth factor (VEGF) nega- tively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003;56(4):922—8.4. Perez-Regadera J. et al. Impact of epi- dermal growth factor (EGFR) expression in desease free survival and rate of pelvic recurrences in advanced cervix cancer patients treated with chemoradiotherapy. ECCO, 2005;13:abstr. 925.Perez-Regadera J. et al. Impact of epi- dermal growth factor (EGFR) expression in desease free survival and rate of pelvic recurrences in advanced cervix cancer patients treated with chemoradiotherapy. ECCO, 2005;13:abstr. 925.5. Randall-Whitis L., Monk B.J., Han E.S. et al. Markers of angiogenesis in cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007, ASCO Annual Meeting Proceedings;25(18S):5536.Randall-Whitis L., Monk B.J., Han E.S. et al. Markers of angiogenesis in cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007, ASCO Annual Meeting Proceedings;25(18S):5536.6. Ramondetta et al. Gyn Onc 2003, P.259-536Ramondetta et al. Gyn Onc 2003, P.259-5367. Mitsuhashi A., Suzuka K., Seki K. et al. Serum vaskular endothelial growth factor (VEGF) and VEGF-c levels as tumor markers in patients with cervical cancer. J Clin Oncol 2005;ASCO Annual Meeting Proceedings;23(16S):5075.Mitsuhashi A., Suzuka K., Seki K. et al. Serum vaskular endothelial growth factor (VEGF) and VEGF-c levels as tumor markers in patients with cervical cancer. J Clin Oncol 2005;ASCO Annual Meeting Proceedings;23(16S):5075.8. Ferreira C.G., Salgado M., Lima R. et al. A phase I trial of erlotinib (E), cis- platin (C) and radiotherapy (RT) for patients with locally advanced squamosus cell cervical cancer. ASCO, 2006; abstr. 13081.Ferreira C.G., Salgado M., Lima R. et al. A phase I trial of erlotinib (E), cis- platin (C) and radiotherapy (RT) for patients with locally advanced squamosus cell cervical cancer. ASCO, 2006; abstr. 13081.9. Ferreira C.G. et al. Journal of Clinical Oncology 26,2008 ASCO (May 20 Supplement),abstr:5511Ferreira C.G. et al. Journal of Clinical Oncology 26,2008 ASCO (May 20 Supplement),abstr:551110. Goncalves A. et al Institut Paoli Calmettes Gynecol Oncol 2008 Jan;108(1):42-6.Epub 2007 Nov 5.Goncalves A. et al Institut Paoli Calmettes Gynecol Oncol 2008 Jan;108(1):42-6.Epub 2007 Nov 5.11. Kurtz E. et al. J Clin Oncol 26:2008 May 20 suppl; 5512Kurtz E. et al. J Clin Oncol 26:2008 May 20 suppl; 551212. Wright J.D. et al. Journal of Clinical Oncology 2006 Nov;103(2):489-93.Epub 2006 May 2.Wright J.D. et al. Journal of Clinical Oncology 2006 Nov;103(2):489-93.Epub 2006 May 2.13. Nimeiri H.S., Oza A.M., Mergan R.J. et al. Sorafenib in patients with advanced uterine carcinoma or carcinosarcoma: a phase II trial of the University of Chicago, PMH, and California Phase II Consortia. J Clin Oncol 2008;26:abstr 5585.Nimeiri H.S., Oza A.M., Mergan R.J. et al. Sorafenib in patients with advanced uterine carcinoma or carcinosarcoma: a phase II trial of the University of Chicago, PMH, and California Phase II Consortia. J Clin Oncol 2008;26:abstr 5585.